TICKERNERD
Menu
SYRESYREHealthcare · Biotechnology

SYRE Stock Forecast: Spyre Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$99
−0.03% on the day

The 18 Wall Street analysts covering Spyre Therapeutics, Inc. hold a median 12-month price target of $123 — +23.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.3B
Ticker Nerd rank
34/ 100
Median analyst target
$123
Analysts covering
18
Revenue$0.0
Operating income−$81.6M
Net income−$36.2M
Free cash flow−$69.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
+6.5%
YTD
+202.9%
1Y
+331.9%
From 52W high
−8.9%
From 52W low
+347.4%
$22
$109
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SYRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spyre Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
34/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Value
81
Quality
54
Volatility
47
Growth
42
Revisions
29
Issuance
28
Accruals
22
Size
16

Momentum (95): The shares have been drifting up relative to others.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SYRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SYRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26SYREHigh $131Median $123Low $110

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
17 Buy1 Hold0 Sell
Low $110Median $123High $131

The green dot is the last close — the median target sits +23.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
4 Nov 2026GuggenheimMaintainsBuy$130 → $135
4 Nov 2026WedbushMaintainsOutperform$123 → $120
19 Oct 2026BTIGReiteratesBuy$121
12 Oct 2026UBSInitiatesBuy$120
1 Oct 2026BTIGReiteratesBuy—
1 Oct 2026BTIGReiteratesBuy$121
1 Oct 2026JP MorganInitiatesOverweight$110
1 Oct 2026JP MorganInitiatesOverweight—
9 Sept 2026WedbushReiteratesOutperform$123
9 Sept 2026WedbushReiteratesOutperform—
8 Sept 2026BTIGReiteratesBuy—
8 Sept 2026BTIGReiteratesBuy$121
26 Aug 2026BTIGMaintainsBuy—
26 Aug 2026BTIGMaintainsBuy$132 → $121
26 Aug 2026Deutsche BankMaintainsBuy$135 → $127
26 Aug 2026Deutsche BankMaintainsBuy—
26 Aug 2026WedbushMaintainsOutperform—
26 Aug 2026WedbushMaintainsOutperform$130 → $123
11 Aug 2026BTIGMaintainsBuy—
11 Aug 2026BTIGMaintainsBuy$112 → $132

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SYRE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SYRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Spyre Therapeutics, Inc. returned +331.9% against +14.8% for the S&P 500, dividends included.

SYRE vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26SYRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SYRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
9
Analysts cutting
3
Fundamentals

Spyre Therapeutics, Inc. (SYRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.7×

Cheaper than 70% of US stocks

Price / sales
—
Price / book
13.4×

Cheaper than 7% of US stocks

EV / EBITDA
−33.8×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−23.0%

Higher than 30% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Spyre Therapeutics, Inc. (SYRE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spyre Therapeutics, Inc. has a market value of $9.3B and an enterprise value of $7.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$178.9M.

  • Diluted earnings per share, trailing twelve months: $−2.05.

  • Free cash flow in the twelve months to 30 June 2026: −$208.9M.

  • Shares outstanding: 88.1M.

  • Trailing P/E: 1.7×; forward P/E: −26.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Spyre Therapeutics, Inc. employs 125 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

SYRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SYRESpyre Therapeutics, Inc.$9.3B34
PTGXProtagonist Therapeutics, Inc.$9.1B97
MDGLMadrigal Pharmaceuticals, Inc.$9.2B80
KRYSKrystal Biotech, Inc.$9.2B88
IBRXImmunityBio, Inc.$9.4B60
TWSTTwist Bioscience Corp.$9.4B69
CAICaris Life Sciences, Inc.$9.4B37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spyre Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SYRE news & analysis

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 3 Nov 2026positive

Spyre Therapeutics reported positive topline induction data for SPY003 in Part A of the Phase 2 SKYLINE trial, completing proof-of-concept for all three IBD monotherapies. Part B is enrolling ahead of schedule, allowing increased enrollment; topline induction results for three potential combinations are expected in Q3 2027.

Why it matters — The update adds clinical proof-of-concept data and outlines the company’s next planned combination results in IBD.

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

GlobeNewsWire · 18 Oct 2026positive

Spyre Therapeutics announced presentations at UEGW 2026 in Barcelona, including the first scientific congress presentation of clinical data across its SPY001, SPY002 and SPY003 IBD antibodies. The company will also present preclinical data on additive efficacy of the antibodies’ complementary mechanisms.

Why it matters — The presentations will provide updates on clinical data for all three antibodies now being tested as monotherapies and pairwise combinations in the SKYLINE study, alongside new preclinical findings.

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Seeking Alpha · 7 Oct 2026positive

Seeking Alpha maintains a Strong Buy rating on Spyre, citing progress in its IBD pipeline and cash reserves. The article notes upcoming PsA, axSpA, and combination readouts after the company discontinued SPY072 monotherapy for RA.

Why it matters — SYRE watchers may track the forthcoming readouts and combination data as updates on the company’s clinical pipeline.

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

GlobeNewsWire · 6 Oct 2026neutral

Spyre Therapeutics announced the pricing of its underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, with expected gross proceeds of approximately $350.0 million. The underwriters were also granted a 30-day option to purchase up to an additional approximately $52.5 million of shares, with the offering expected to close on or about October 7, 2026.

Why it matters — SYRE watchers would care because the offering details the company's capital raise, including share pricing, gross proceeds, and underwriter option terms ahead of the anticipated closing.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

GlobeNewsWire · 5 Oct 2026neutral

Spyre Therapeutics announced it has commenced an underwritten public offering of its common stock, and expects to grant underwriters a 30-day option to purchase an additional 15% of the shares offered under the same terms. The offering is subject to market and other conditions, with no assurance as to completion or final size or terms.

Why it matters — A public stock offering could affect Spyre's share count and capital position, which SYRE shareholders typically watch closely.

FAQ

Frequently asked questions about SYRE stock

What is the SYRE stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Spyre Therapeutics, Inc. have a median 12-month price target of $123, with estimates ranging from $110 to $131. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SYRE stock a buy right now?

Of the 18 analysts covering Spyre Therapeutics, Inc., 17 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spyre Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SYRE?

As at 4 Nov 2026, Spyre Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will SYRE stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +23.9% from the last close, and Ticker Nerd's factor model ranks Spyre Therapeutics, Inc. 34 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SYRE stock forecast for 2030?

No analyst covering Spyre Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $131 over the next 12 months.

How has SYRE stock performed over the past year?

Spyre Therapeutics, Inc. returned +331.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spyre Therapeutics, Inc. do?

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders.

What is the latest news on SYRE?

The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update". Spyre Therapeutics reported positive topline induction data for SPY003 in Part A of the Phase 2 SKYLINE trial, completing proof-of-concept for all three IBD monotherapies. Part B is enrolling ahead of schedule, allowing increased enrollment; topline induction results for three potential combinations are expected in Q3 2027.

Company

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment durability, and simplify dosing for patients with ulcerative colitis, Crohn’s disease, and related rheumatic conditions. Its current pipeline centers on investigational antibody programs targeting key immune pathways, including α4β7, TL1A, and IL-23, with both standalone and combination approaches under development. The company is primarily engaged in biopharmaceutical research and clinical development, and its work is centered on creating next-generation immunology treatments for complex chronic diseases. Headquartered in Waltham, Massachusetts, Spyre Therapeutics serves as a specialized player in the biotech sector, where it contributes to the advancement of targeted therapies for gastrointestinal and immune-mediated diseases.

CEO Dr. Cameron Turtle DPHIL, Ph.D. · 125 employees · United States · https://www.spyre.com